The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT02876328
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project (PREVAIL)

Active Ingredients

Drugs in Phase 2 Trials (4)

ad26.zebov (Zabdeno) (1 trial)

mva-bn-filo (Mvabea) (1 trial)

rvsv (1 trial)

rvsvdelta-zebov-gp (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhagic Fever, Ebola (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 4